NDLI: Effect and factors associated with reactivation after intravitreal conbercept or aflibercept in retinopathy of prematurity

Content Provider	Springer Nature : BioMed Central
Author	Huang, Chunling Zou, Weikang Ma, Wenbei Li, Jiali Bai, Yichen Wu, Rong Li, Qiqi Fang, Qi Chen, Wenna Lu, Xiaohe Feng, Songfu
Abstract	Background To evaluate the effect and factors associated with the reactivation of retinopathy of prematurity (ROP) after intravitreal conbercept or aflibercept. Methods We retrospectively reviewed the medical records of 176 eyes diagnosed with ROP and treated with anti-VEGF therapy between January 2018 and September 2022. The rate of reactivation and complications were assessed during the follow-up period. The factors of reactivation of ROP after intravitreal conbercept or aflibercept were analyzed on the basis of clinical factors and retinal parameters. Results Reactivation of ROP occurred in 10 eyes (13.9%) after intravitreal conbercept and 13 eyes (12.5%) after intravitreal aflibercept (P = 0.79). The interval between injection and reactivation was significantly longer in the aflibercept group than in the conbercept group (15.50 ± 4.05 vs. 5.36 ± 0.50 weeks) (P < 0.001). The central retinal arteriolar equivalent (CRAE) of aggressive ROP was larger than that of type 1 prethreshold and threshold ROP before anti-VEGF therapy (P < 0.05). Zone I and stage 3 exhibited a positive correlation with the reactivation of retinopathy of prematurity (ROP) [odds ratio (OR) = 20.15, 5.02]. The changes in CRAE of pre-and post-therapy and gestational age were identified as potential protective factors for these outcomes (OR = 0.23, 0.49). Conclusions Conbercept and aflibercept are effective for treating ROP. Aflibercept resulted in longer treatment intervals compared to conbercept. Zone, stage, and gestational age were associated with the reactivation of ROP. CRAE was associated with not only the severity of ROP but also its reactivation. Additionally, it may be an objective indicator in the early indication and follow-up of ROP.
Related Links	https://eurjmedres.biomedcentral.com/counter/pdf/10.1186/s40001-024-02206-7.pdf
Ending Page	7
Page Count	7
Starting Page	1
File Format	HTM / HTML
DOI	10.1186/s40001-024-02206-7
Journal	European Journal of Medical Research
Issue Number	1
Volume Number	30
Language	English
Publisher	BioMed Central
Publisher Date	2025-01-28
Access Restriction	Open
Subject Keyword	Medicine Public Health Infectious Diseases Internal Medicine Surgery Oncology Biomedicine Aflibercept Anti-vascular endothelial growth factor Conbercept Reactivation Retinal vessels Retinopathy of prematurity Medicine/Public Health
Content Type	Text
Resource Type	Article
Subject	Medicine
Journal Impact Factor	2.8/2023
5-Year Journal Impact Factor	2.9/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Characteristics of Eyes Developing Retinal Detachment After Anti-vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity

Progression of retinal vascularization after intravitreal anti-vascular-endothelial growth factor therapy in retinopathy of prematurity

Short-term effects of intravitreal anti-vascular endothelial growth factor agents on body weight and multiple systems after treatment for retinopathy of prematurity

Efficacy of four anti-vascular endothelial growth factor agents and laser treatment for retinopathy of prematurity: A network meta-analysis.

Comparison of Clinical Outcomes of Intravitreal Bevacizumab and Aflibercept in Type 1 Prethreshold Retinopathy of Prematurity in Posterior Zone II.

Intravitreal Anti-vascular Endothelial Growth Factor Injection for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis

Intravitreal anti-vascular endothelial growth factor treatment for retinal diseases

Vascular endothelial growth factor in gingival crevicular fluid around dental implants

Anti-vascular endothelial growth factor therapy for age-related macular degeneration: a systematic review and network meta-analysis

Effect and factors associated with reactivation after intravitreal conbercept or aflibercept in retinopathy of prematurity

Similar Documents

Characteristics of Eyes Developing Retinal Detachment After Anti-vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity

Progression of retinal vascularization after intravitreal anti-vascular-endothelial growth factor therapy in retinopathy of prematurity

Short-term effects of intravitreal anti-vascular endothelial growth factor agents on body weight and multiple systems after treatment for retinopathy of prematurity

Efficacy of four anti-vascular endothelial growth factor agents and laser treatment for retinopathy of prematurity: A network meta-analysis.

Comparison of Clinical Outcomes of Intravitreal Bevacizumab and Aflibercept in Type 1 Prethreshold Retinopathy of Prematurity in Posterior Zone II.

Intravitreal Anti-vascular Endothelial Growth Factor Injection for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis

Intravitreal anti-vascular endothelial growth factor treatment for retinal diseases

Vascular endothelial growth factor in gingival crevicular fluid around dental implants

Anti-vascular endothelial growth factor therapy for age-related macular degeneration: a systematic review and network meta-analysis

Effect and factors associated with reactivation after intravitreal conbercept or aflibercept in retinopathy of prematurity